CURRENT METHODS OF EARLY DIAGNOSIS OF PROSTATE CANCER


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Prostate cancer is the most common cancer among men, except for lung cancer. Therefore, it is imperative to identify diagnostic methods for early detection of prostate cancer to determine patients from healthy populations, which helps guide a timely treatment at an initial stage of the disease. The article provides an in-depth review of the most current diagnostic biomarkers of prostate cancer, their role in clinical practice as a means of the early detection and screening for prostate cancer.

Full Text

Restricted Access

About the authors

A. V Govorov

A.I. Evdokimov Moscow State University of Medicine and Dentistry

Email: dr.govorov@gmail.com
Dr.Med.Sci., Associate Professor at the Department of Urology Moscow, Russia

A. O Vasilyev

A.I. Evdokimov Moscow State University of Medicine and Dentistry

Email: alexvasilyev@me.com
PhD, Teaching Assistant at the Department of Urology Moscow, Russia

A. A Shiryaev

A.I. Evdokimov Moscow State University of Medicine and Dentistry

Email: eschief2@gmail.com
Department of Urology Resident Moscow, Russia

S. O Sukhikh

A.I. Evdokimov Moscow State University of Medicine and Dentistry

Email: docsukhikh@gmail.com
Department of Urology PhD researcher Moscow, Russia

A. V Sidorenkov

S.I. Spasokukotsky Municipal Clinical Hospital

Email: avsid-v@mail.ru
urologist Moscow, Russia

A. V Pushkarev

N.E. Bauman Moscow State Technical University

Email: pushkarev@bmstu.ru
engineer of1st category, Power Engineering Research Institute Moscow, Russia

D. I Tsiganov

N.E. Bauman Moscow State Technical University

Email: dtsiganov@yandex.ru
Dr.Engin.Sci., prof., Lead Engineer, Power Engineering Research Institute Moscow, Russia

D. Yu Pushkar’

A.I. Evdokimov Moscow State University of Medicine and Dentistry

Email: pushkardm@mail.ru
corresponding member of RAS, Dr.Med.Sci., Prof., Head of the Department of Urology Moscow, Russia

References

  1. Kolontarev K.B., Govorov A.V., Osipova Т.А., Sidorenkov A.V., Pushkar D.Y. The value ofthe -2proPSA and the prostate health index for prostate cancer patients: review and data from the Russian prospective study. Urologia. 2015;1:49-53.
  2. Pushkar D.Y., Govorov A.V., Sidorenkov A.V. Prilepskaya E.A., Kovilina M.V. Early diagnostic of prostate cancer. Guidelines № 19. M.: OOO Publishing house «ABV-press». 2015;52 p.
  3. Sidorenkov A.V., Govorov A.V., Sadchenko A.V., Pushkar D.Y. The diagnostic value of [-2]proPSA and PHI (review). Oncourology. 2014;4:87-95.
  4. Vasilyev A.O., Prilepskaya E.A., Kovylina M.V., Govorov A.V., Sadchenko A.V., Sidorenkov A.V., Pushkar D.Y. Modern markers and histological features of prostate cancer. Urologia. 2016;6:164-166.
  5. Bussemakers M.J., VanBokhoven А., Verhaegh G. W., Smit F.P., Karthaus H. F., Schalken J.A., Debruyne F.M., Ru N., Isaacs W.B. DD3: a new prostate-specific gene, highly overexpressed in prostate cancer. Cancer Res. 1999;59(23):5975-5979.
  6. Haese A., de la Taille A., van Poppel H. Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy. Eur Urol. 2008;54:1081-1088.
  7. Gittelman M.C., Hertzman B., Bailen J. PCA3 molecular urine test as a predictor of repeat prostate biopsy outcome in men with previous negative biopsies: a prospective multicenter clinical study. J Urol. 2013;190:64-69.
  8. Bradley L.A., Palomaki G.E., Gutman S. Comparative effectiveness review: prostate cancer antigen 3 testing for the diagnosis and management of prostate cancer. J Urol. 2013;190:389-398.
  9. Chevli K.K., Duff M., Walter P. Urinary PCA3 as a predictor of prostate cancer in a cohort of 3,073 men undergoing initial prostate biopsy. J Urol. 2014;191:1743-1748.
  10. Wei J.T., Feng Z., Partin A.W. Can urinary PCA3 supplement PSA in the early detection of prostate cancer? J Clin Oncol. 2014;32:4066-4072.
  11. Salami S.S., Schmidt F., Laxman B., Regan M.M., Rickman D.S., Scherr D. Combining urinary detection of TMPRSS2:ERG and PCA3 with serum PSA to predict diagnosis of prostate cancer. Urol Oncol. 2013; 31:566-571.
  12. Russo G.I., Regis F., Castelli T., Favilla V., Privitera S., Giardina R., Cimino S., Morgia G. A systematic review and meta-analysis of the diagnostic accuracy of prostate health index and four-kallikrein panel score in predicting overall and high-grade prostate cancer, Clinical Genitourinary Cancer. 2016;1558-7673(16)30368-8.
  13. Porpiglia F., Cantiello F., De Luca S. In-parallel comparative evaluation between multiparametric magnetic resonance imaging, prostate cancer antigen 3 and the Prostate Health Index in predicting pathologically confirmed significant prostate cancer in men eligible for active surveillance. BJU Int. 2016;118:527-534.
  14. Seisen T., Roupret M., Brault D. Accuracy of the Prostate Health Index versus the urinary prostate cancer antigen 3 score to predict overall and significant prostate cancer at initial biopsy. Prostate. 2015;75:103-111.
  15. Ferro M., Lucarelli G., Bruzzese D. Improving the prediction of pathologic outcomes in patients undergoing radical prostatectomy: the value of prostate cancer antigen 3 (PCA3), Prostate Health Index (phi) and sarcosine. Anticancer Res. 2015;35:1017-1023.
  16. Fenstermaker M., Mendhiratta N., Bjurlin M.A. Risk stratification by urinary prostate cancer gene 3 testing before magnetic resonance imagingultrasound fusion-targeted prostate biopsy among men with no history of biopsy. Urology. 2017;99:174-179.
  17. Dani H., Loeb S. The role of prostate cancer biomarkers in undiagnosed men. Curr Opin Urol. 2017;27(3):210-216.
  18. Makarov D.V., Isharwal S., Sokoll L.J., Landis P., Marlow C., Epstein J.I., Partin A.W., Carter H.B., Veltri R.W. Pro-prostate-specific antigen measurements in serum and tissue are associated with treatment necessity among men enrolled in expectant management for prostate cancer. Clin. Cancer Res. 2009;150:7316-7321.
  19. Catalona W.J., Partin A.W., Sanda M.G. A multicenter study of [ 2]pro-prostate specific antigen combined with prostate specific antigen and free prostate specific antigen for prostate cancer detection in the 2.0 to 10.0 ng/ ml prostate specific antigen range. J Urol. 2011;185:1650-1655.
  20. Loeb S., Sanda M.G., Broyles D.L. The Prostate Health Index selectively identifies clinically significant prostate cancer. J Urol. 2015; 193:1163- 1169.
  21. De la Calle C., Patil D., Wei J.T. Multicenter evaluation of the Prostate Health Index to detect aggressive prostate cancer in biopsy naive men. J Urol. 2015;194:65-72.
  22. Lughezzani G., Lazzeri M., Haese A. Multicenter European external validation of a Prostate Health Index-based nomogram for predicting prostate cancer at extended biopsy. Eur Urol. 2014;66:906-912.
  23. Foley R.W., Maweni R.M., Gorman L. European Randomised Study of Screening for Prostate Cancer (ERSPC) risk calculators significantly outper- form the Prostate Cancer Prevention Trial (PCPT) 2.0 in the prediction of prostate cancer: a multi-institutional study. BJU Int. 2016;118:706-713.
  24. Lin D.W., Newcomb L.F., Brown M.D., Sjoberg D.D., Dong Y., Brooks J.D., Carroll P.R., Cooperberg M., Dash A., Ellis W.J., Fabrizio M., Gleave M.E., Morgan T.M., Nelson P.S., Thompson I.M., Wagner A.A., Zheng Y. Evaluating the Four Kallikrein Panel of the 4Kscore for Prediction of High-grade Prostate Cancer in Men in the Canary Prostate Active Surveillance Study. Eur Urol. 2016;23:S0302-2838(16);30850-8.
  25. Zappala S.M., Dong Y., Linder V., Reeve M., Sjoberg D.D., Mathur V., Roberts R., Okrongly D., Newmark J., Sant G., Steiner M. The 4Kscore blood test accurately identifies men with aggressive prostate cancer prior to prostate biopsy with or without DRE information. Int J Clin Pract. 2017;7(6):122-128.
  26. Voigt J.D., Dong Y., Linder V., Zappala S. Use of the 4Kscore test to predict the risk of aggressive prostate cancer prior to prostate biopsy: Overall cost savings and improved quality of care to the us healthcare system. Rev Urol. 2017;19(1):1-10.
  27. Borque-Fernando Á., Esteban-Escaño L.M., Rubio-Briones J., Lou-Mercadé A.C., García-Ruiz R., Tejero-Sánchez A., Muñoz-Rivero M.V., Cabañuz-Plo T., Alfaro- Torres J., Marquina-Ibáñez I.M., Hakim-Alonso S., Mejía-Urbáez E., Gil-Fabra J., Gil-Martínez P., Ávarez-Alegret R., Sanz G., Gil-Sanz M.J. A Preliminary Study of the Ability of the 4Kscore test, the Prostate Cancer Prevention Trial-Risk Calculator and the European Research Screening Prostate-Risk Calculator for Predicting High-Grade Prostate Cancer. Actas Urol Esp. 2016;40(3): 155-163.
  28. Bryant RJ., Sjoberg D.D., Vickers A.J., Robinson M.C., Kumar R., Marsden L., Davis M., Scardino P.T., Donovan J., Neal D.E., Lilja H., Hamdy F.C. Predicting high-grade cancer at ten-core prostate biopsy using four kallikrein markers measured in blood in the ProtecT study. J Natl Cancer Inst. 2015;107(7):djv095.
  29. Tomlins S.A., Bjartell A., Chinnaiyan A.M., Jenster G., Nam R.K., Rubin M.A., Schalken J.A. ETS gene fusions in prostate cancer: from discovery to daily clinical practice. Eur Urol. 2009;56(2):275-286.
  30. Tomlins S.A., Aubin S.M., Siddiqui J. Urine TMPRSS2:ERG fusion transcript stratifies prostate cancer risk in men with elevated serum PSA. Sci Transl Med. 2011;3:94ra72.
  31. Tomlins S.A., Day J.R., Lonigro R.J., Hovelson D.H., Siddiqui J., Kunju L.P., Dunn R.L., Meyer S., Hodge P., Groskopf J., Wei J.T., Chinnaiyan A.M. Urine TMPRSS2:ERG Plus PCA3 for Individualized Prostate Cancer Risk Assessment. Eur Urol. 2016;70(1):45-53.
  32. Van Neste L., Hendriks R.J., Dijkstra S. Detection of high-grade prostate cancer using a urinary molecular biomarker-based risk score. Eur Urol. 2016;70:740-748.
  33. Partin A.W., Van Neste L., Klein E.A. Clinical validation of an epigenetic assay to predict negative histopathological results in repeat prostate biopsies. J Urol. 2014;192:1081-1087.
  34. Stewart G.D., Van Neste L., Delvenne P. Clinical utility of an epigenetic assay to detect occult prostate cancer in histopathologically negative biop- sies: results of the MATLOC study. J Urol. 2013; 189: 1110-1116.
  35. Melling N., Taskin B., Hube-Magg C., Kluth M., Minner S., Koop C., Grob T., Graefen M., Heinzer H., Tsourlakis M.C., Izbicki J., Wittmer C., Huland H., Simon R., Wilczak W., Sauter G., Steurer S., Schlomm T., Krech T. Cytoplasmic accumulation of ELAVL1 is an independent predictor of biochemical recurrence associated with genomic instability in prostate cancer. Prostate. 2016;76(3):259-272.
  36. Hori S.S., Lutz A.M., Paulmurugan R., Gambhir S.S. A Model-Based Personalized Cancer Screening Strategy for Detecting Early-Stage Tumors Using Blood-Borne Biomarkers. Cancer Res. 2017;77( 10) : 2570-2584.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies